Clinical Research Directory
Browse clinical research sites, groups, and studies.
Bezafibrate in Patients With Primary Biliary Cholangitis (PBC)
Sponsor: University of Aarhus
Summary
Up to 40% of patients with PBC have an inadequate response to standard treatment with UDCA, hence bezafibrate, a PPAR-agonist is being introduced as add-on therapy in these patients. sCD163, fibrosis markers and bile acid composition are of special interest in PBC. In this study, the investigators will investigate how treatment with bezafibrate influence levels of macrophage activation markers and fibrosis markers as well as bile acid composition in patients offered bezafibrate as add-on therapy to UDCA.
Official title: Measuring Macrophage Activation Markers and Influence on Bile Acid Composition in Patients With Primary Biliary Cholangitis After Treatment With Bezafibrate
Key Details
Gender
All
Age Range
18 Years - 99 Years
Study Type
OBSERVATIONAL
Enrollment
100
Start Date
2020-10-01
Completion Date
2026-09
Last Updated
2022-08-12
Healthy Volunteers
No
Conditions
Interventions
Blood sampling
Blood sampling
Fibroscan
Measurement of liver stiffness
Question
Question about pruritus
Locations (2)
Department of Hepatology and Gastroenterology, Aarhus University Hospital, Denmark
Aarhus N, Central Jutland, Denmark
Department of Medicine, Gastrounit Medical division
Hvidovre, Denmark